Literature DB >> 35747889

Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease.

Andrew McGarry1, Peggy Auinger1, Karl D Kieburtz1, Amy-Lee Bredlau1, Steven M Hersch1, H Diana Rosas1.   

Abstract

Background and
Objectives: Suicidality is a common concern in the routine care of persons with Huntington disease (HD) and for the many participants in HD clinical trials. In a previous analysis, we identified baseline and time-dependent factors associated with suicidal ideation and attempts from 2CARE, a large, randomized, double-blind clinical trial.
Methods: The present analysis extends our prior methodology to 2 other large interventional HD clinical trials, CARE-HD and CREST-E.
Results: We observed relationships across studies between suicidality events and prior suicidal ideation at baseline, antidepressant/anxiolytic use, chorea, increasing age, and several domains in the Unified Huntington Disease Rating Scale (UHDRS) Behavioral Assessment (depressed mood, low self-esteem, aggression, and active suicidality). Discussion: These data may form the basis for a subscale of demographic and UHDRS items with the potential for prospectively identifying suicidality risk in HD clinics and clinical trials. Trial Registration Information: 2CARE and CREST are registered at clinicaltrials.gov. 2CARE NCT00608881, registered February 6, 2008; first enrollment March 2008. CREST-E NCT00712426, registered July 10, 2008; first enrollment September 2009. CARE-HD, not registered; first enrollment July 1997.
© 2022 American Academy of Neurology.

Entities:  

Year:  2022        PMID: 35747889      PMCID: PMC9208406          DOI: 10.1212/CPJ.0000000000001161

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  15 in total

1.  Early Huntington's Disease: Impulse Control Deficits but Correct Judgment Regarding Risky Situations.

Authors:  Victor Galvez; Juan Fernandez-Ruiz; Leo Bayliss; Adriana Ochoa-Morales; Carlos R Hernandez-Castillo; Rosalinda Díaz; Aurelio Campos-Romo
Journal:  J Huntingtons Dis       Date:  2017

2.  Prior suicide attempts predict worse clinical and functional outcomes in young people attending a mental health service.

Authors:  Frank Iorfino; Daniel F Hermens; Shane P M Cross; Natalia Zmicerevska; Alissa Nichles; Josine Groot; Adam J Guastella; Elizabeth M Scott; Ian B Hickie
Journal:  J Affect Disord       Date:  2018-06-14       Impact factor: 4.839

3.  Risk-Taking Behaviors in Huntington's Disease.

Authors:  Katherine E McDonell; Abagail E Ciriegio; Anna C Pfalzer; Lisa Hale; Shuhei Shiino; Heather Riordan; Sarah Moroz; R Ryan Darby; Bruce E Compas; Daniel O Claassen
Journal:  J Huntingtons Dis       Date:  2020

4.  Self-reported impulsivity in Huntington's disease patients and relationship to executive dysfunction and reward responsiveness.

Authors:  Patricia L Johnson; Geoffrey F Potts; Juan Sanchez-Ramos; Cynthia R Cimino
Journal:  J Clin Exp Neuropsychol       Date:  2016-11-28       Impact factor: 2.475

5.  Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs.

Authors:  Jennifer A Simpson; Debra Lovecky; Jane Kogan; Louise A Vetter; George J Yohrling
Journal:  J Huntingtons Dis       Date:  2016-12-15

6.  A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.

Authors: 
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

7.  Predicting Future Suicide Attempts Among Adolescent and Emerging Adult Psychiatric Emergency Patients.

Authors:  Adam G Horwitz; Ewa K Czyz; Cheryl A King
Journal:  J Clin Child Adolesc Psychol       Date:  2014-05-28

Review 8.  Risk-taking and pathological gambling behavior in Huntington's disease.

Authors:  Carla Kalkhoven; Cor Sennef; Ard Peeters; Ruud van den Bos
Journal:  Front Behav Neurosci       Date:  2014-04-02       Impact factor: 3.558

9.  Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial.

Authors:  Andrew McGarry; Michael P McDermott; Karl Kieburtz; Wai Lun Alan Fung; Elizabeth McCusker; Jing Peng; Elisabeth A de Blieck; Merit Cudkowicz
Journal:  Neurology       Date:  2019-03-08       Impact factor: 9.910

10.  A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

Authors:  Andrew McGarry; Michael McDermott; Karl Kieburtz; Elisabeth A de Blieck; Flint Beal; Karen Marder; Christopher Ross; Ira Shoulson; Peter Gilbert; William M Mallonee; Mark Guttman; Joanne Wojcieszek; Rajeev Kumar; Mark S LeDoux; Mary Jenkins; H Diana Rosas; Martha Nance; Kevin Biglan; Peter Como; Richard M Dubinsky; Kathleen M Shannon; Padraig O'Suilleabhain; Kelvin Chou; Francis Walker; Wayne Martin; Vicki L Wheelock; Elizabeth McCusker; Joseph Jankovic; Carlos Singer; Juan Sanchez-Ramos; Burton Scott; Oksana Suchowersky; Stewart A Factor; Donald S Higgins; Eric Molho; Fredy Revilla; John N Caviness; Joseph H Friedman; Joel S Perlmutter; Andrew Feigin; Karen Anderson; Ramon Rodriguez; Nikolaus R McFarland; Russell L Margolis; Eric S Farbman; Lynn A Raymond; Valerie Suski; Sandra Kostyk; Amy Colcher; Lauren Seeberger; Eric Epping; Sherali Esmail; Nancy Diaz; Wai Lun Alan Fung; Alan Diamond; Samuel Frank; Philip Hanna; Neal Hermanowicz; Leon S Dure; Merit Cudkowicz
Journal:  Neurology       Date:  2016-12-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.